These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10309192)

  • 1. Effectiveness of a cephalosporin education program--a pharmacy education program.
    Sohn CA; Wolter HA; McSweeney GW
    Drug Intell Clin Pharm; 1980 Apr; 14(4):272-7. PubMed ID: 10309192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
    Cramer R; Wright C
    Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacist impact on parenteral cephalosporin prescribing.
    Lawlor MC; Lucarotti RL
    Hosp Formul; 1983 Apr; 18(4):402-4, 407-8. PubMed ID: 10259512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Savings achieved through cephalosporin surveillance.
    Katz E; Schlamowitz S
    Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of an education program on cefazolin prescribing.
    Blain L; O'Brodovich M
    Can J Hosp Pharm; 1989 Apr; 42(2):69-71. PubMed ID: 10292923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug usage review and inventory analysis in promoting rational parenteral cephalosporin therapy.
    Simon WA; Thompson L; Campbell S; Lantos RL
    Am J Hosp Pharm; 1975 Nov; 32(11):1116-21. PubMed ID: 1190230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of parenteral cephalosporin regulation on pharmacy costs.
    Ryan JL; Francese J
    Hosp Formul; 1983 May; 18(5):510-2. PubMed ID: 10260198
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of education on cephalosporin prescribing patterns.
    Frye CB; Baker B; Sexton DJ; Dougherty FK
    J Okla State Med Assoc; 1987 Sep; 80(9):649-53. PubMed ID: 3668708
    [No Abstract]   [Full Text] [Related]  

  • 10. Controlling financial variables--changing prescribing patterns.
    Abramowitz PW
    Am J Hosp Pharm; 1984 Mar; 41(3):503-15. PubMed ID: 6367444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital.
    Woodward RS; Medoff G; Smith MD; Gray JL
    Am J Med; 1987 Nov; 83(5):817-23. PubMed ID: 3674089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling moxalactam and cefotaxime use with a target drug program.
    Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG
    Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial impact of formulary revision of second-generation cephalosporins.
    Andrews JD; Hafting S
    Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost containment through restriction of cephalosporins.
    Britton HL; Schwinghammer TL; Romano MJ
    Am J Hosp Pharm; 1981 Dec; 38(12):1897-900. PubMed ID: 7325168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems.
    Schentag JJ; Paladino JA; Birmingham MC; Zimmer G; Carr JR; Hanson SC
    J Pharm Technol; 1995; 11(5):203-10. PubMed ID: 10151512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy.
    Caldwell RD; Davis SK
    Hosp Pharm; 1987 Dec; 22(12):1205-9. PubMed ID: 10285375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there cost reduction potential for extended half-life cephalosporins?
    Scalley RD; Stuart CC
    Drug Intell Clin Pharm; 1986 Dec; 20(12):975-80. PubMed ID: 3816548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacy U.R. cuts costs, drug use.
    Mosier RL
    Hosp Peer Rev; 1979 May; 4(5):70-2. PubMed ID: 10308905
    [No Abstract]   [Full Text] [Related]  

  • 19. Changing prescribing patterns: a program of physician education.
    Whiteside ME; Lefkowitz S; Justiniani FR; Ratzan K
    Hosp Formul; 1987 Jun; 22(6):561-3, 566, 568. PubMed ID: 10282249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
    Hayman JN; Sbravati EC
    Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.